2024-08-28 18:40:03
The Ministry of Health will present its plan to combat dengue fever in 2025 in September this year, with measures focusing on environmental control strategies, epidemiological surveillance and care of the most severe cases of the disease.
There is still no clear definition for expanding dengue vaccination coverage. Currently, the vaccine is only available to children and adolescents aged 10 to 14 years. The vaccine is authorized by the National Health Supervision Agency (Anvisa) and is suitable for people aged 4 to 60 years old.
Also read Health Butantan’s dengue vaccine remains effective in 3.7 years. Loss Brazil’s Health Directorate recommends states expand dengue vaccination coverage. understand
Health Minister Nísia Trindade explained that mass vaccination is not yet a feasible strategy because the manufacturer – Takeda Laboratories – has production difficulties. “Vaccines are a strategy that we will continue to use, but it is not the main strategy in 2025. It may be the main strategy in 2026, depending on the development of the butantan vaccine,” Trindade said at a breakfast meeting with reporters on Wednesday. (28/8).
Takeda and Butantan
One possibility for expanding vaccine supply is a technology transfer agreement, as AstraZeneca and the Osvaldo Cruz Foundation (Fiocruz) have done during the pandemic. Negotiations are continuing, but difficulties are being faced in providing the inputs needed for vaccine production, according to the health ministry.
Meanwhile, the government is awaiting final approval for the dengue vaccine produced by the Butantan Institute.
Butantan vaccine consists of a genetically attenuated virus that protects against four types of dengue viruses. According to the research center, “A 17,000-volunteer clinical trial in collaboration with multiple states is in the final stages of obtaining registration for Anvisa.
Takeda’s vaccine is administered in two doses and also uses an attenuated virus to induce an immune response. In clinical trials, the vaccine proved effective against the four existing serotypes of the virus. In private clinics, the vaccination costs approximately R$ 450.00 per dose.
This year, Brazil experienced a historic dengue fever epidemic. According to the Ministry of Health’s Arbovirus Team, there have been 6.4 million cases of the disease and at least 5,204 deaths.
Focus on health editorial No Instagram And stay informed about everything about this topic!
1724894104
#Dengue #Expansion #vaccine #target #audience #confirmed #September
